Duloxetine in the treatment of stress urinary incontinence

Journal of Pharmacy Technology

Volumn 21, Issue 6, 2005, Pages 337-340

  Osborne, Kristie L ^a   Davis, Steven M ^b,c  

^a Greever's Drug Store   (United States)

^b CAMPBELL UNIVERSITY   (United States)

^c WAKE FOREST BAPTIST HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DULOXETINE; NORADRENALIN; PLACEBO; SEROTONIN;

BLADDER FILLING; CLINICAL TRIAL; CONSTIPATION; DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; HUMAN; INSOMNIA; NAUSEA; PATIENT COMPLIANCE; QUALITY OF LIFE; REVIEW; STRESS INCONTINENCE; UNITED STATES; XEROSTOMIA;

EID: 28944432639     PISSN: 87551225     EISSN: None     Source Type: Journal    
DOI: 10.1177/875512250502100605     Document Type: Review

References (18)

1. Stedman's medical dictionary. 27th ed. Baltimore: Lippincott Williams & Wilkins, 2000:888.
2. Rovner ES, Wyman J, Lackner T, Guay D. Urinary incontinence. In: Dipiro JX Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach. 5th ed. New York: McGraw Hill, 2002:1543-56.
3. Luber KM. The definition, prevalence, and risk factors for stress urinary incontinence. Rev Urol 2004;6(suppl 3):S3-9.
4. Wall LL, Davidson TG. The role of muscular re-education by physical therapy in the treatment of genuine stress urinary incontinence. Obstet Gynecol Surv 1992;47:322-31.
5. Cammu H, Van Nylen M. Pelvic floor muscle exercises: 5 years later. Urology 1995;45:113-8.
6. Fantl JA, Newman DK, Colling J, DeLancey JO, Keeys C, Loughery R, et al. Urinary incontinence in adults: acute and chronic management. Clinical practice guideline, no. 2, AHCPR publication no. 96-0682. Rockville, MD: Public Health Service, Agency for Health Care Policy and Research.
7. Package insert. Cymbalta (duloxetine). Eli Lilly, 1996, updated September 2004. http://pi.lilly.com/us/cymbalta-pi.pdf (accessed 2004 Nov 6).
8. DuBeau CE. Treatment of urinary incontinence. UpToDate. http://utdol.com (accessed 2004 Nov 16).
9. Lilly and Boehringer Ingelheim jointly announce the recision of US FDA application for duloxetine for treatment of stress urinary incontinence. Lilly, January 28, 2005. http://newsroom.lilly.com/ReleaseDetail.cfm?ReleaseID=154081 (accessed 2005 Mar 17).
10. Jost WH, Marsalek P. Duloxetine: mechanism of action at the lower urinary tract and Onuf's nucleus. Clin Auton Res 2004;14:220-7.
11. Katofiasc MA, Nissen J, Audia JE, Thor KB. Comparison of the effects of serotonin selective, norepinephrine selective, and dual serotonin and norepinephrine reuptake inhibitors on lower urinary tract function in cats. Life Sci 2002;71:1227-36.
12. Norton PA, Zinner NR, Yalcin I, Bump RC. Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol 2002;187:40-8.
13. Dmochowski RR, Miklos JR, Norton PA, Zinner NR, Yalcin I, Bump RC. Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. J Urol 2003;70:1259-63.
14. Millard RJ, Moore K, Rencken R, Yalcin I, Bump RC. Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial. BJU Int 2004;93:311-8.
15. Van Kerrebroeck P, Abrams P, Lange R, Slack M, Wyndaele JJ, Yalcin I, et al. Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence. BJOG Int J Obstet Gynaecol 2004;111:249-57.
16. Cardozo L, Drutz HP, Baygani SK, Bump RC. Pharmacological treatment of women awaiting surgery for stress urinary incontinence. Obstet Gynecol 2004;104:511-9.
17. Yalcin I, Bump RC. Validation of two global impression questionnaires for incontinence. Am J Obstet Gynecol 2003;189:98-101.
18. Patrick DL, Martin ML, Bushnell DM, Yalcin I, Wagner TH, Buesching DP. Quality of life of women with urinary incontinence: further development of the incontinence quality of life instrument (1-QOL). Urology 1999;53:71-6.